Safety considerations associated with BiTE^® molecules

BiTE^® molecules, are designed to engage the body’s endogenous T cells to target and help eliminate cancer cells.¹ BiTE^® molecules, like other T-cell–based immuno-oncology therapies, may be associated with specific treatment-related adverse events (AEs), such as immune effector cell–associated neurotoxicity syndrome (ICANS; previously known as neurotoxicity), that require specific management strategies.²